Search Result

Results for "

multiple sclerosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADC Antibody (1) Adenosine Deaminase (2) Adenosine Receptor (1) Adrenergic Receptor (2) Apoptosis (11) Autophagy (3) Btk (3) Cannabinoid Receptor (2) Cathepsin (1) CCR (1) CD19 (1) CD20 (2) Cholinesterase (ChE) (1) CXCR (2) DNA/RNA Synthesis (1) EBV (1) Endogenous Metabolite (6) Epigenetic Reader Domain (1) FABP (1) FKBP (1) Glutaminase (1) GSK-3 (2) Histamine Receptor (1) HIV (3) iGluR (1) Integrin (4) Interleukin Related (6) Isotope-Labeled Compounds (3) Keap1-Nrf2 (6) LPL Receptor (16) LXR (1) MAGL (2) MAP3K (1) Mas-related G-protein-coupled Receptor (MRGPR) (1) MEK (1) Mitochondrial Metabolism (1) MMP (3) Monoamine Oxidase (2) NF-κB (4) NOD-like Receptor (NLR) (2) p38 MAPK (1) PAI-1 (2) Phosphatase (2) Phosphodiesterase (PDE) (2) Phospholipase (1) PKC (1) Potassium Channel (3) Proteasome (1) Protein Arginine Deiminase (4) Reactive Oxygen Species (3) ROR (4) Ser/Thr Protease (2) Sodium Channel (1) TGF-beta/Smad (3) TNF Receptor (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (12) Endocrinology (3) Infection (4) Inflammation/Immunology (86) Metabolic Disease (9) Neurological Disease (50)

By Targets:

5-HT Receptor (1)

ADC Antibody (1)

Adenosine Deaminase (2)

Adenosine Receptor (1)

Adrenergic Receptor (2)

Apoptosis (11)

Autophagy (3)

Btk (3)

Cannabinoid Receptor (2)

Cathepsin (1)

CCR (1)

CD19 (1)

CD20 (2)

Cholinesterase (ChE) (1)

CXCR (2)

DNA/RNA Synthesis (1)

EBV (1)

Endogenous Metabolite (6)

Epigenetic Reader Domain (1)

FABP (1)

FKBP (1)

Glutaminase (1)

GSK-3 (2)

Histamine Receptor (1)

HIV (3)

iGluR (1)

Integrin (4)

Interleukin Related (6)

Isotope-Labeled Compounds (3)

Keap1-Nrf2 (6)

LPL Receptor (16)

LXR (1)

MAGL (2)

MAP3K (1)

Mas-related G-protein-coupled Receptor (MRGPR) (1)

MEK (1)

Mitochondrial Metabolism (1)

MMP (3)

Monoamine Oxidase (2)

NF-κB (4)

NOD-like Receptor (NLR) (2)

p38 MAPK (1)

PAI-1 (2)

Phosphatase (2)

Phosphodiesterase (PDE) (2)

Phospholipase (1)

PKC (1)

Potassium Channel (3)

Proteasome (1)

Protein Arginine Deiminase (4)

Reactive Oxygen Species (3)

ROR (4)

Ser/Thr Protease (2)

Sodium Channel (1)

TGF-beta/Smad (3)

TNF Receptor (1)

By Research Areas:

Cancer (30)

Cardiovascular Disease (12)

Endocrinology (3)

Infection (4)

Inflammation/Immunology (86)

Metabolic Disease (9)

Neurological Disease (50)

113

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Divozilimab BCD-132	CD20	Inflammation/Immunology
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .

TRV-7019	Cholinesterase (ChE)	Neurological Disease Cancer
TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity .

FABPs ligand 6 MF6	FABP	Inflammation/Immunology
FABPs ligand 6 (MF6) is an FABP5 and FABP7 inhibitor with K_D values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research .

ZK824190 hydrochloride 1 Publications Verification	Ser/Thr Protease PAI-1	Inflammation/Immunology
ZK824190 hydrochloride is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC₅₀s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively .

Ocrelizumab	CD20	Inflammation/Immunology
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .

VK-1727	EBV	Infection Inflammation/Immunology Cancer
VK-1727 is a selective small molecule inhibitor of EBNA1. VK-1727 can reduce EBNA1 DNA binding activity. VK-1727 selectively blocks the proliferation and metabolic activity of EBV+ cells, instead of EBV- cells. VK-1727 is used in multiple sclerosis research .

Inebilizumab 1 Publications Verification	ADC Antibody CD19	Inflammation/Immunology
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .

Daclizumab Zenapax; Ro 24-7375	Interleukin Related	Inflammation/Immunology Cancer
Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research .

VSN-16	Cannabinoid Receptor	Cardiovascular Disease Inflammation/Immunology
VSN-16 is a cannabinoid receptor agonist with vasodilatory activity. VSN-16 can be used for the study of multiple sclerosis .

ZK824190	Ser/Thr Protease PAI-1	Inflammation/Immunology
ZK824190 is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC₅₀s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively .

CXCR3 antagonist 1	CXCR	Inflammation/Immunology
CXCR3 antagonist 1 (compound 6c) is a selective and non-cytotoxic CXCR3 antagonist (IC₅₀=0.06 µM). CXCR3 antagonist 1 has potential in researching inflammatory diseases (including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes) .

Myelin Basic Protein(87-99)	Others	Inflammation/Immunology
Myelin Basic Protein(87-99) is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS) .

Fingolimod phosphate 1 Publications Verification FTY720 phosphate	LPL Receptor	Infection Neurological Disease Inflammation/Immunology
Fingolimod phosphate (FTY720 phosphate) is an orally active sphingosine 1-phosphate (S1P) receptor agonist. Fingolimod phosphate can promote the neuroprotective effects of microglia. Fingolimod phosphate can be used for the research of multiple sclerosis and neurologic diseases .

Heptadecanoic acid 1 Publications Verification	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis .

CTPS1-IN-2	DNA/RNA Synthesis	Inflammation/Immunology Cancer
CTPS1-IN-2 (P115) is an inhibitor of Cytidine Triphosphate Synthase 1 (CTPS1) with an IC₅₀ value of ≤ 0.1 μM. CTPS1-IN-2 can be used for research on cancer (such as leukemia and lymphoma), inflammatory skin diseases (such as psoriasis), or multiple sclerosis .

Tolebrutinib 4 Publications Verification SAR442168; PRN2246	Btk	Neurological Disease
Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of Bruton tyrosine kinase (BTK), with IC₅₀s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib exhibits efficacy in central nervous system immunity. Tolebrutinib can be used for the research of multiple sclerosis (MS) .

ML404	Others	Cardiovascular Disease Neurological Disease
ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC₅₀=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke .

BJJF078	Glutaminase	Inflammation/Immunology
BJJF078 is an aminopiperidine derivative. BJJF078 is a potent inhibitor of recombinant human and mouse Transglutaminase enzyme (TG2) activity, IC₅₀ values of 41 and 54 nM, respectively. BJJF078 also inhibits the close related enzyme TG1, with an IC₅₀ of 0.16 μM. BJJF078 can be used for Multiple sclerosis (MS) research .

HPPE Bach1-IN-1	Mitochondrial Metabolism	Metabolic Disease
HPPE (compound 236) is an orally active, potential Bach1 inhibitor. Bach1 is a transcription factor of the cap'n'collar type alkaline region leucine zipper factor family (CNC-bZip) that regulates mitochondrial metabolism and reduces glucose utilization. HPPE can be used for research in psoriasis, multiple sclerosis, and COPD .

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

BRD5075	Interleukin Related	Inflammation/Immunology
BRD5075 is a potent GPR65 activator. BRD5075 induces GPR65-dependent cAMP production. BRD5075 decreases the gene expression of IL-1, IL-2, TNF, and chemokine. BRD5075 has the potential for the research of multiple sclerosis and inflammatory bowel disease (IBD) .

Rovelizumab	Integrin	Cardiovascular Disease
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .

FKGK11	Phospholipase	Neurological Disease Inflammation/Immunology Cancer
FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis .

MRGPRX4 modulator-2	Mas-related G-protein-coupled Receptor (MRGPR)	Inflammation/Immunology
MRGPRX4 modulator-2 (compound 1-55) is a potent MRGPR X4 modulator, possessing antagonist activity against MRGPR X4 with an IC₅₀ < 100 nM. MRGPRX4 modulator-2 can be used for researching autoimmune diseases such as psoriasis, multiple sclerosis, Steven Johnson’s Syndrome, and other chronic itch conditions .

AK 295 CX 295	Proteasome Apoptosis	Neurological Disease
AK 295 (CX 295) is a calpain inhibitor that inhibits apoptosis through a calpain-dependent pathway. AK 295 improves neurological function in a rat model of spinal cord injury (SCI). AK 295 can be used in the study of neurodegenerative diseases, such as bulbar amyotrophy, stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis .

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

S1P1 agonist 5	LPL Receptor	Inflammation/Immunology
S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS) .

Glatiramer acetate	Others	Inflammation/Immunology Cancer
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression .

Firategrast 5+ Cited Publications SB 683699	Integrin	Neurological Disease
Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .

Laquinimod-d5 ABR-215062-d₅	Isotope-Labeled Compounds Apoptosis NF-κB	Inflammation/Immunology
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

Siponimod 5+ Cited Publications BAF-312	LPL Receptor	Neurological Disease Inflammation/Immunology
Siponimod (BAF-312) is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P₁ and S1P₅ over S1P₂, S1P₃, and S1P₄, with EC₅₀s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research ^- .

Laquinimod 2 Publications Verification ABR-215062	NF-κB Apoptosis	Inflammation/Immunology
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has?the?potential?for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases?research .

Laquinimod sodium ABR-215062 sodium	NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

PTPσ Inhibitor, ISP	Phosphatase	Neurological Disease
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .

Siponimod hemifumarate BAF-312 hemifumarate	LPL Receptor	Neurological Disease Inflammation/Immunology
Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC₅₀s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research .

R079	Keap1-Nrf2	Neurological Disease Inflammation/Immunology
R079 (compound 17) is a selective, orally active Nrf2 activator. R079 increases Nrf2 translocation activity (EC₅₀ = 32.41 μM). R079 can neutralize excess levels of reactive oxygen species through activating Nrf2. R079 has anti-inflammatory properties and can be used in multiple sclerosis research .

Natalizumab (Solution) 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

RORγt modulator 3	ROR	Neurological Disease Inflammation/Immunology Cancer
RORγt modulator 3 (Compound 23) is a modulator of retinoid-related orphan receptor γt (RORγt). RORγt modulator 3 can be used for the research of RORyt mediated diseases such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer .

A-971432	Others	Neurological Disease
A-971432 is a potent, selective and orally active sphingosine-1-phosphate (S1P) receptor 5 agonist with IC₅₀s of .362, >10, 0.006 µM for S1P1, S1P3, S1P5 respectively. A-971432 protects blood–brain barrier (BBB) homeostasis. A-971432 reverses age-related cognitive decline. A-971432 has the potential for the research of alzheimer’s disease or multiple sclerosis .

Siponimod (Standard)	LPL Receptor	Neurological Disease Inflammation/Immunology
Siponimod (Standard) is the analytical standard of Siponimod. This product is intended for research and analytical applications. Siponimod (BAF-312) is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P₁ and S1P₅ over S1P₂, S1P₃, and S1P₄, with EC₅₀s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research ^- .

RORγt modulator 2	ROR	Neurological Disease Inflammation/Immunology Cancer
RORγt modulator 2 (Compound 21) is a modulator of retinoid-related orphan receptor γt (RORγt) with the IC₅₀ of <50 nM. RORγt modulator 2 can be used for the research of RORyt mediated diseases such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer .

Laquinimod (Standard)	NF-κB Apoptosis	Inflammation/Immunology
Laquinimod (Standard) is the analytical standard of Laquinimod. This product is intended for research and analytical applications. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

Frexalimab SAR441344; INX-021	TNF Receptor	Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sjögren’s syndrome and type I diabetes research .

MAGLi 432	MAGL	Neurological Disease Inflammation/Immunology
MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC₅₀ values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease .

Cladribine 4 Publications Verification 2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA	Adenosine Deaminase Apoptosis	Cardiovascular Disease Cancer
Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis .

Cat. No.	Product Name

HY-L105

Peptide Library

1,663 compounds

Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain.

MedChemExpress (MCE) offers a comprehensive collection of 1,663 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

HY-L070

Neuroprotective Compound Library

1,133 compounds

Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases.

MCE offers a unique collection of 1,133 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P1052A

Myelin Basic Protein(87-99) TFA	Peptides	Inflammation/Immunology
Myelin Basic Protein(87-99) TFA is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) TFA causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS) .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P3724

MBP (146-170)	Peptides	Inflammation/Immunology
MBP (146-170) is a myelin basic protein (MBP). MBP (146-170) can be used for the research of multiple sclerosis (MS) .

HY-P10297

PLP (190-209)	Peptides	Inflammation/Immunology
PLP (190-209) is a myelin proteolipid protein (PLP) fragment. PLP (190-209) is used to induce experimental autoimmune encephalomyelitis (EAE) animal models for multiple sclerosis research .

HY-P10532

Myelin basic protein, MBP (68-86)	Peptides	Others Inflammation/Immunology
Myelin basic protein, MBP (68-86) is the portion of the 68th to 86th amino acid residues in the MBP protein sequence. Myelin basic protein, MBP (68-86) can act as an autoantigen, triggering the immune system to attack its own myelin. Myelin basic protein, MBP (68-86) is used as one of the immunogens in the experimental autoimmune encephalomyelitis (EAE) animal model to study immune responses associated with multiple sclerosis (MS) .

HY-P3541

Dirucotide MBP8298	Peptides	Neurological Disease Inflammation/Immunology
Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein. Dirucotide can be used for the research in autoimmune disorder of the central nervous system, such as Multiple sclerosis (MS) .

HY-P1996

Tiplimotide NBI-5788	Peptides	Neurological Disease Inflammation/Immunology
Tiplimotide (NBI-5788) is an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP). Tiplimotide can selectively reduce the production of inflammatory cytokines by pathogenic T-cells. Tiplimotide can be used for the research of multiple sclerosis (MS) .

HY-P5982

PTPσ Inhibitor, ISP	Phosphatase	Neurological Disease
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .

HY-P5462

PLP (180-199)	Peptides	Others
PLP (180-199) is a biological active peptide. (This is amino acids 180-199 fragment of myelin proteolipid protein (PLP). PLP, the most abundant myelin protein of the central nervous system, has been used in multiple sclerosis (MS) studies. MS is a chronic inflammatory demyelinating disease of the CNS.)

HY-P10522

MBP Ac1-9	Peptides	Others
MBP Ac1-9 refers to a peptide fragment of myelin basic protein (MBP). MBP Ac1-9 is an immunodominant epitope in the experimental autoimmune encephalomyelitis (EAE) model, which can induce T cell immune response and lead to pathological changes similar to multiple sclerosis. MBP Ac1-9 can be used to study T cell activation and autoimmune response .

HY-P2791

Tertiapin (reduced)	Potassium Channel	Neurological Disease Inflammation/Immunology
Tertiapin (reduced) is a kind of synthesis of melittin, its Cys3-Cys14 and Cys5-Cys18 between containing a disulfide bond. Tertiapin (reduced) is a kind of inward rectifier potassium channels blockers, can block the activity of calcium activates large conductance potassium channels. Tertiapin (reduced) can be used for research in diseases such as rheumatoid arthritis and multiple sclerosis .

HY-P5462A

PLP (180-199) TFA	Peptides	Inflammation/Immunology
PLP (180-199) TFA is the TFA salt form of PLP (180-199) (HY-P5462). PLP (180-199) TFA induces the activation and differentiation of T cells, and induces the experimental autoimmune encephalomyelitis (EAE) in mouse model .

HY-P5121

γ-Fibrinogen 377-395	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

HY-P5121A

γ-Fibrinogen 377-395 TFA	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 TFA is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 TFA blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 TFA can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

HY-P2459

MOG (35-55), human	Peptides	Neurological Disease
MOG (35-55), human is a component of CNS myelin. MOG (35-55), human is different from mMOG (35-55) by a proline for serine substitution at position 42. MOG (35-55), human is also immunogenic, but not encephalitogenic, and is only partially cross-reactive with mMOG35–55. MOG (35-55), human induces minimal clinical signs of EAE relative to the rodent peptide .

HY-P1789

CTTHWGFTLC, CYCLIC	MMP	Inflammation/Immunology Cancer
CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC₅₀ value for MMP-9 is ~8 μM .

HY-P1789A

CTTHWGFTLC, CYCLIC TFA	MMP	Inflammation/Immunology Cancer
CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC₅₀ value for MMP-9 is ~8 μM .

HY-P10525

MBP Ac1-9 (4Y)	Peptides	Neurological Disease
MBP Ac1-9 (4Y) is a synthetic peptide derived from a fragment of myelin basic protein (MBP) that has undergone specific chemical modifications. MBP Ac1-9 (4Y) is able to form a complex with the MHC class II molecule I-Au and activate specific T cell receptor (TCR), thus playing a role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE). MBP Ac1-9 (4Y) can be used to study autoimmune diseases, especially those involving the central nervous system, such as multiple sclerosis .

Cat. No.	Product Name	Target	Research Area

HY-P99855

Divozilimab BCD-132	CD20	Inflammation/Immunology
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .

HY-P99780

Opicinumab BIIB033	Inhibitory Antibodies	Inflammation/Immunology
Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis .

HY-P9960

Ocrelizumab	CD20	Inflammation/Immunology
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .

HY-P99113

Inebilizumab 1 Publications Verification	ADC Antibody CD19	Inflammation/Immunology
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .

HY-108738

Daclizumab Zenapax; Ro 24-7375	Interleukin Related	Inflammation/Immunology Cancer
Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research .

HY-P99524

Vatelizumab GBR500	Inhibitory Antibodies	Inflammation/Immunology
Vatelizumab (GBR500) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). Vatelizumab can be used for the research of multiple sclerosis .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P99891

Rovelizumab	Integrin	Cardiovascular Disease
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .

HY-108831A

Natalizumab (Solution) 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-P99213

Ozanezumab GSK1223249	Inhibitory Antibodies	Neurological Disease
Ozanezumab (GSK1223249) is an anti-Nogo-A (neurite outgrowth inhibitor A) monoclonal antibody. Ozanezumab can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research .

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sjögren’s syndrome and type I diabetes research .

HY-P99335

Vunakizumab Anti-Human IL17A Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .

HY-P99113A

Inebilizumab (FUT8-KO)	Inhibitory Antibodies	Inflammation/Immunology
Inebilizumab (FUT8-KO) is Inebilizumab with the fucosyltransferase 8 gene (FUT8) knocked out. Inebilizumab (HY-P99113) is a monoclonal antibody (mAb) targeting CD19, exhibiting enhanced antibody-dependent cellular cytotoxicity (ADCC) against B cells. Inebilizumab can be used for research on multiple sclerosis and neuromyelitis optica .

HY-108831

Natalizumab 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

Cat. No.	Product Name	Chemical Structure

HY-13010S

Laquinimod-d5

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-W004284S

Heptadecanoic acid-d3
Heptadecanoic acid-d₃ is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis[1].

HY-W004284S1

Heptadecanoic acid-d33
Heptadecanoic acid-d₃₃ is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis[1].

HY-17363S1

Dimethyl fumarate-d2

Dimethyl fumarate-d₂ is the deuterium labeled Dimethyl fumarate[1]. Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research[2][3].

HY-B1139S

Tolperisone-d10 hydrochloride

Tolperisone-d₁₀ (hydrochloride) is the deuterium labeled Tolperisone hydrochloride. Tolperisone hydrochloride is a centrally acting muscle relaxant, is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.

HY-12355S

Siponimod-d11
Siponimod-d11 is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P₁ and S1P₅ over S1P₂, S1P₃, and S1P₄, with EC₅₀s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks